Augmentation of current antidepressant (SSRI) with ziprasidone (40 mg/d to 160 mg/d) vs augmentation of current antidepressant (SSRI) with placebo or continue on SSRI monotherapy
Quality of life ‐ not measured · treatment‐resistant depression in adults
The review found no eligible studies for this question.
1 finding from 1 review
- Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found